These unique therapies treat well-defined medical conditions, replacing missing or deficient proteins found in plasma, to allow their recipients to lead healthier and more productive lives. The patient populations that rely upon plasma protein therapies generally require regular infusions or injections for the duration of their lives.
Plasma-derived therapies and their recombinant analogs, collectively referred to as plasma protein therapies, are unique, biologic medicines, versus synthetic or chemical medicines, because production begins with plasma, a biologic starting material. Each therapy has its own unique biochemical profile, due to differences in production and processing methods, which results in different clinical responses and efficacy among patients.
Plasma protein therapies are not interchangeable and have been defined by regulators as sole-source biologic products because no generics or substitutions exist. In addition, their biological nature demands storage and handling requirements by specialty distributors that ensure their safety.
Plasma protein therapies are unique, biologic medicines that are either infused or injected to treat a variety of rare, life-threatening, chronic and genetic diseases. Learn more about the therapies used to treat these diseases and the patients who rely on plasma protein therapies.
PPTA Proudly Supports World Hemophilia Day 2017 +
Register now for the 2017 Plasma Protein Forum! +
The 2017 Plasma Protein Forum will be held Tuesday, June 13 - Wednesday, June 14 at the Washington Marriott Georgetown in Washington, D.C.
Registration for the Forum includes access to all general sessions, the exhibit hall and all Forum breaks (you must be registered in order to participate in any of the Forum activities).Read More
The Hilfenhaus Award conferred to Prof. Farkas at the IPPC 2017 +
The 2017 Hilfenhaus Award was bestowed to Professor Henriette Farkas, MD, Ph.D., DSc, during IPPC 2017 for her work related to treating those suffering from Hereditary Angioedema (HAE) and working to improve treatments and patients’ quality of life. She is professor of allergology and clinical immunology at the Hungarian Angioedema Center at Semmelweis University in Budapest, Hungary.Read More
Chief Executive of the Irish Haemophilia Society on PPTs